Prognostic role of effective radiation dose to immune cells in esophageal cancer treated with definitive chemoradiation
PLOS One · 2025
DOI: 10.1371/journal.pone.0336794 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Yoo Kyung Choi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Chemoradiotherapy. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Radiotherapy for locally advanced esophageal cancer can induce lymphopenia, potentially worsening outcomes. This study examines the association between clinical outcomes and the effective dose to the immune cells (EDIC), a measure of lymphocyte radiation exposure.
Methods
We retrospectively analyzed 107 patients with locally advanced esophageal squamous cell carcinoma treated with definitive concurrent chemoradiotherapy (CCRT). The EDIC was calculated based on the mean lung dose, mean heart dose, and integral total body dose using established models. Patients were stratified into high (n = 42) and low (n = 65) effective dose to the immune cells (EDIC) groups using a cut-off value of 4.28 Gy. Survival outcomes, including overall survival (OS), progression-free survival (PFS), locoregional failure-free survival (LRFS), and distant metastasis-free survival (DMFS), were assessed.
Results
The 5-year OS and PFS rates were significantly lower in the high EDIC group than in the low EDIC group (51.9% vs. 66.6%, p = 0.043; 20.8% vs. 31.8%, p = 0.002, respectively). Multivariate analysis identified high EDIC as an independent predictor of poorer OS (hazard ratio (HR): 2.06, 95% confidence interval (CI): 1.1–3.86, p = 0.024) and PFS (HR: 1.7, 95% CI: 1.04–2.78, p = 0.034). Similarly, the 5-year LRFS and DMFS rates were significantly lower in the high EDIC group than in the low EDIC group (24.1% vs. 34.9%, p = 0.003; 29.0% vs. 44.0%, p = 0.018, respectively).
Conclusion
A higher EDIC is an independent predictor of poor survival in patients with esophageal squamous cell carcinoma undergoing CCRT. Reducing radiation exposure to the immune system through optimized radiation planning and lymphocyte-sparing techniques may improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
ORCID-Profile: Yoo Kyung Choi, Hong Seok Jang, Soo-Yoon Sung
Zitieren
APA
Choi, Y. K., Son, S. H., Jang, H. S., Kim, I. H., Lee, S. W., & Sung, S. Y. (2025). Prognostic role of effective radiation dose to immune cells in esophageal cancer treated with definitive chemoradiation. PLOS One. https://doi.org/10.1371/journal.pone.0336794
Vancouver
Choi YK, Son SH, Jang HS, Kim IH, Lee SW, Sung SY. Prognostic role of effective radiation dose to immune cells in esophageal cancer treated with definitive chemoradiation. PLOS One. 2025. doi:10.1371/journal.pone.0336794
BibTeX
@article{Choi2025,
author = {Choi, Yoo Kyung and Son, Seok Hyun and Jang, Hong Seok and Kim, In-Ho and Lee, Sea-Won and Sung, Soo-Yoon},
title = {Prognostic role of effective radiation dose to immune cells in esophageal cancer treated with definitive chemoradiation},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0336794}
}
EUVIMED